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The immunopathogenic mechanisms responsible for
debilitating neurodegenerative and oncologic diseases
associated with human T-cell leukemia virus type 1
(HTLV-1) are not fully understood. In this respect, a
patient cohort from HTLV-1 endemic region that
included seronegative controls (controls), asymptomatic
carriers (ACs), and patients with adult T-cell leukemia
(ATL) or HTLV-associated myelopathy/tropical spastic
paraparesis (HAM/TSP) was analyzed for CD8+ T cells
functionality in response to the viral antigen Tax and a
superantigen SEB. Overall, there was a poor recall
response to Tax and less polyfunctionality in cells from
ATL and HAM/TSP patients but not in ACs explaining
why these cells remain ineffective in limiting viral bur-
den and controlling disease progression. On the other
hand, response to superantigen SEB was similar in all
the groups, suggesting that the observed defects in CD8
+ T cells are not generalized but rather HTLV-specific.
As an underlying mechanism, programmed death-1
(PD-1) receptor was found to be highly unregulated in
Tax-responsive cells from ATL and HAM/TSP but not
from ACs and directly correlated with the lack of poly-
functionality in these individuals. Further, an opposite
dynamic was observed between PD-1 and MIP-1a with
proviral loads revealing new avenues of understanding
the immunopathogenesis of human chronic viral infec-
tions. Additionally, we identified key cytokine signatures
defining the immune activation status of clinical samples
by the luminex analyses. Collectively, our findings suggest
that reconstitution of fully functional CTLs, stimulation
of MIP-1a expression, and/or blockade of the PD-1 path-
way as potential approaches for immunotherapy and
therapeutic vaccine against HTLV-mediated diseases.
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